Literature DB >> 27787448

SMOKING IS A RISK FACTOR FOR PROLIFERATIVE VITREORETINOPATHY AFTER TRAUMATIC RETINAL DETACHMENT.

Dean Eliott1, Tomasz P Stryjewski, Michael T Andreoli, Christopher M Andreoli.   

Abstract

PURPOSE: To determine the incidence of retinal redetachment due to proliferative vitreoretinopathy after open-globe trauma in smokers and nonsmokers.
METHODS: A total of 892 patients comprising 893 open-globe injuries, in whom 255 eyes were diagnosed with a retinal detachment, and 138 underwent surgical repair were analyzed in a retrospective case-control study. Time to redetachment was examined using the Kaplan-Meier method and analysis of risk factors was analyzed using Cox proportional hazards modeling.
RESULTS: Within one year after retinal detachment surgery, 47% (95% CI, 39-56%) of all 138 repaired retinas redetached because of proliferative vitreoretinopathy. Being a smoker was associated with a higher rate of detachment (adjusted hazard ratio 1.96, P = 0.01). As shown in previous studies, the presence of proliferative vitreoretinopathy at the time of surgery was also an independent risk factor for failure (adjusted hazard ratio 2.13, P = 0.005). Treatment with vitrectomy-buckle compared favorably to vitrectomy alone (adjusted hazard ratio 0.58, P = 0.04). Only 8% of eyes that redetached achieved a best-corrected visual acuity of 20/200 or better, in comparison to 44% of eyes that did not redetach (P < 0.001).
CONCLUSION: Proliferative vitreoretinopathy is a common complication after the repair of retinal detachment associated with open-globe trauma, and being a smoker is a risk factor for redetachment. Further study is needed to understand the pathophysiologic mechanisms underlying this correlation.

Entities:  

Mesh:

Year:  2017        PMID: 27787448     DOI: 10.1097/IAE.0000000000001361

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

Review 1.  Proliferative Vitreoretinopathy: A Review.

Authors:  Sana Idrees; Jayanth Sridhar; Ajay E Kuriyan
Journal:  Int Ophthalmol Clin       Date:  2019

2.  Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy.

Authors:  Dhanesh Amarnani; Arturo Israel Machuca-Parra; Lindsay L Wong; Christina K Marko; James A Stefater; Tomasz P Stryjewski; Dean Eliott; Joseph F Arboleda-Velasquez; Leo A Kim
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-08-01       Impact factor: 4.799

3.  Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy.

Authors:  Santiago Delgado-Tirado; Dhanesh Amarnani; Guannan Zhao; Elizabeth J Rossin; Dean Eliott; John B Miller; Whitney A Greene; Leslie Ramos; Said Arevalo-Alquichire; David Leyton-Cifuentes; Lucia Gonzalez-Buendia; Daniela Isaacs-Bernal; Hannah A B Whitmore; Natalia Chmielewska; Brandon V Duffy; Eric Kim; Heuy-Ching Wang; Jose M Ruiz-Moreno; Leo A Kim; Joseph F Arboleda-Velasquez
Journal:  Sci Rep       Date:  2020-11-30       Impact factor: 4.379

Review 4.  Managing PVR in the Era of Small Gauge Surgery.

Authors:  Manish Nagpal; Rakesh Juneja; Sham Talati
Journal:  J Ophthalmol       Date:  2021-12-04       Impact factor: 1.909

Review 5.  More than Meets the Eye: The Aryl Hydrocarbon Receptor is an Environmental Sensor, Physiological Regulator and a Therapeutic Target in Ocular Disease.

Authors:  Christine L Hammond; Elisa Roztocil; Vardaan Gupta; Steven E Feldon; Collynn F Woeller
Journal:  Front Toxicol       Date:  2022-03-03

6.  TNF-α and NF-κB signaling play a critical role in cigarette smoke-induced epithelial-mesenchymal transition of retinal pigment epithelial cells in proliferative vitreoretinopathy.

Authors:  Victor Wang; Alison Heffer; Elisa Roztocil; Steven E Feldon; Richard T Libby; Collynn F Woeller; Ajay E Kuriyan
Journal:  PLoS One       Date:  2022-09-01       Impact factor: 3.752

7.  Clinical Outcomes of Rhegmatogenous Retinal Detachment Treated With Pneumatic Retinopexy.

Authors:  Nicolas A Yannuzzi; Charles Li; Danielle Fujino; Scott P Kelly; Flora Lum; Harry W Flynn; D Wilkin Parke
Journal:  JAMA Ophthalmol       Date:  2021-06-17       Impact factor: 8.253

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.